ImmuniCell® in Patients With Advanced Cancers

Summary

To determine the safety, tolerability, maximum tolerated dose (MTD) and efficacy of ImmuniCell® in patients with melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC). The study is an adaptive design that has 3 stages: Stage 1 - dose escalation, Stage 2 - efficacy, and Stage 3 - confirm efficacy in one of the tumor types.

Timeline

Start

2015-12

Primary completion

2018-11-27

Completion

2018-11-27

Drugs

Indications